Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury

Marco Failla, Tiziana Genovese, Emanuela Mazzon, Elisa Gili, Carmelo Muià, Mariangela Sortino, Nunzio Crimi, Achille P. Caputi, Salvatore Cuzzocrea, Carlo Vancheri

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.

Original languageEnglish
Article number137
JournalRespiratory Research
Volume7
DOIs
Publication statusPublished - Dec 21 2006

Fingerprint

Leukotrienes
Acute Lung Injury
Bleomycin
verlukast
zileuton
Animal Models
Pharmacology
Lung Injury
Lung
Peroxidase
Dimercaprol
Interleukin-1
Collagen
Cell Count
Staining and Labeling
Leukotriene Antagonists
Lipoxygenase Inhibitors
Idiopathic Pulmonary Fibrosis
Gene Knockout Techniques
Neutrophil Infiltration

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. / Failla, Marco; Genovese, Tiziana; Mazzon, Emanuela; Gili, Elisa; Muià, Carmelo; Sortino, Mariangela; Crimi, Nunzio; Caputi, Achille P.; Cuzzocrea, Salvatore; Vancheri, Carlo.

In: Respiratory Research, Vol. 7, 137, 21.12.2006.

Research output: Contribution to journalArticle

Failla, M, Genovese, T, Mazzon, E, Gili, E, Muià, C, Sortino, M, Crimi, N, Caputi, AP, Cuzzocrea, S & Vancheri, C 2006, 'Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury', Respiratory Research, vol. 7, 137. https://doi.org/10.1186/1465-9921-7-137
Failla, Marco ; Genovese, Tiziana ; Mazzon, Emanuela ; Gili, Elisa ; Muià, Carmelo ; Sortino, Mariangela ; Crimi, Nunzio ; Caputi, Achille P. ; Cuzzocrea, Salvatore ; Vancheri, Carlo. / Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. In: Respiratory Research. 2006 ; Vol. 7.
@article{34b60fc533e245edae4eb74e2c0d7ddd,
title = "Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury",
abstract = "Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.",
author = "Marco Failla and Tiziana Genovese and Emanuela Mazzon and Elisa Gili and Carmelo Mui{\`a} and Mariangela Sortino and Nunzio Crimi and Caputi, {Achille P.} and Salvatore Cuzzocrea and Carlo Vancheri",
year = "2006",
month = "12",
day = "21",
doi = "10.1186/1465-9921-7-137",
language = "English",
volume = "7",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury

AU - Failla, Marco

AU - Genovese, Tiziana

AU - Mazzon, Emanuela

AU - Gili, Elisa

AU - Muià, Carmelo

AU - Sortino, Mariangela

AU - Crimi, Nunzio

AU - Caputi, Achille P.

AU - Cuzzocrea, Salvatore

AU - Vancheri, Carlo

PY - 2006/12/21

Y1 - 2006/12/21

N2 - Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.

AB - Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.

UR - http://www.scopus.com/inward/record.url?scp=33845484030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845484030&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-7-137

DO - 10.1186/1465-9921-7-137

M3 - Article

C2 - 17118201

AN - SCOPUS:33845484030

VL - 7

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 137

ER -